Clinical Trials
43 trialsNCT02159989 2025-10-20
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT03712904 2025-09-24
Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma
Thomas Jefferson University
Phase 2 Terminated
NCT00532155 2025-09-10
VITAL
Sanofi
Phase 3 Completed
NCT01652196 2025-02-05
Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT02384759 2024-07-10
FOLFA
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT00407654 2024-03-04
VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01782443 2023-08-14
Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03710564 2023-01-30
MERLIN
Novartis
Phase 3 Terminated
NCT02181556 2021-06-07
Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT02340949 2021-05-03
RIA
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2 Completed
NCT00437034 2021-02-08
Aflibercept for Relapsed Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00794417 2020-12-10
A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma
Regeneron Pharmaceuticals
Phase 1/2 Terminated
NCT02101918 2020-03-23
Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01669720 2020-02-17
C261
Brown University
Phase 2 Terminated
NCT01747551 2020-02-10
FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00462826 2019-07-23
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01258855 2019-05-10
Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00436501 2019-02-26
VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01661972 2018-10-29
X-TRAP
Duke University
Phase 1/2 Completed
NCT00450255 2018-05-24
VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01571284 2018-04-17
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Sanofi
Phase 3 Completed
NCT02192541 2018-03-29
Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT00828139 2017-08-21
S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00357760 2017-06-23
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00729157 2017-03-15
Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT01882868 2017-03-14
A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan
Sanofi
Phase 2 Completed
NCT01749956 2017-02-07
5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01670721 2016-11-28
AFEQT
Sanofi
Phase 3 Completed
NCT01661270 2016-10-18
AFLAME
Sanofi
Phase 3 Completed
NCT00519285 2016-07-22
VENICE
Sanofi
Phase 3 Completed
NCT00327171 2016-06-07
Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer
Sanofi
Phase 2 Completed
NCT00574275 2016-06-07
VANILLA
Sanofi
Phase 3 Terminated
NCT00851084 2016-06-07
AFFIRM
Sanofi
Phase 2 Completed
NCT01955629 2016-04-18
AMOR
Sanofi
Phase 1/2 Terminated
NCT00390234 2015-12-07
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00369590 2015-10-02
VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide
National Cancer Institute (NCI)
Phase 2 Completed
NCT00509249 2015-01-08
Aflibercept in Treating Patients With Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00407485 2014-10-20
VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium
National Cancer Institute (NCI)
Phase 2 Completed
NCT00369655 2014-05-05
VEGF Trap in Treating Patients With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00396591 2013-01-10
AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
Sanofi
Phase 2 Completed
NCT00327444 2013-01-01
Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
Sanofi
Phase 2/3 Completed
NCT00284141 2012-12-10
Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma
Sanofi
Phase 2 Completed
NCT00561470 2012-09-28
VELOUR
Sanofi
Phase 3 Completed